


Politique d’Investissement Responsable – Juin 2025

Augustine Therapeutics announces first patient dosed in Phase I for the treatment of Charcot-Marie-Tooth disease

SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025
